Qualification and Clinical Validation of an Immunodiagnostic Assay for Detecting 11 Additional *Streptococcus pneumoniae* Serotype-specific Polysaccharides in Human Urine

Warren V. Kalina,1 Victor Souza,1 Kangjian Wu,1 Peter Giordano,1 Andrew McKeen,1 Qin Jiang,2 Charles Tan,2 Roger French,2 Yanhua Ren,1 Kelly Belanger,1 Susan McElhiney,1 Manu Unnithan,1 Huiming Cheng,1 Terri Mininni,1 Donna Giordano-Schmidt,1 Bradford D. Gessner,4 Kathrin U. Jansen,1 and Michael W. Pride1

1Vaccine Research and Development, Pfizer Research, Pearl River, New York, USA, 2Early Clinical Development, Pfizer Research, Pearl River, New York, USA, 3Global Clinical Affairs, Pfizer, Collegeville, Pennsylvania, USA, and 4Medical and Scientific Affairs, Pfizer, Collegeville, Pennsylvania, USA

**Background.** Identifying *Streptococcus pneumoniae* serotypes by urinary antigen detection (UAD) assay is the most sensitive way to evaluate the epidemiology of nonbacteremic community-acquired pneumonia (CAP). We first described a UAD assay to detect the *S. pneumoniae* serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F, covered by the licensed 13-valent *S. pneumoniae* conjugate vaccine. To assess the substantial remaining pneumococcal disease burden after introduction of several pneumococcal vaccines, a UAD-2 assay was developed to detect 11 additional serotypes (2, 8, 9N, 10A, 11A, 12F, 15B, 17F, 20, 22F, and 33F) in individuals with radiographically confirmed CAP.

**Methods.** The specificity of the UAD-2 assay was achieved by capturing pneumococcal polysaccharides with serotype-specific monoclonal antibodies, using Luminex technology. Assay qualification was used to assess accuracy, precision, and sample linearity. Serotype positivity was based on cutoffs determined by nonparametric statistical evaluation of urine samples from individuals without pneumococcal disease. The sensitivity and specificity of the positivity cutoffs were assessed in a clinical validation, using urine samples obtained from a large study that measured the proportion of radiographically confirmed CAP caused by *S. pneumoniae* serotypes in hospitalized US adults.

**Results.** The UAD-2 assay was shown to be specific and reproducible. Clinical validation demonstrated assay sensitivity and specificity of 92.2% and 95.9% against a reference standard of bacteremic pneumonia. In addition, the UAD-2 assay identified a *S. pneumoniae* serotype in 3.72% of nonbacteremic CAP cases obtained from hospitalized US adults. When combined with bacteremic CAP cases, the proportion of pneumonias with a UAD-2 serotype was 4.33%.

**Conclusions.** The qualified/clinically validated UAD-2 method has applicability in understanding the epidemiology of nonbacteremic *S. pneumoniae* CAP and for assessing the efficacy of future pneumococcal conjugate vaccines that are under development.

**Keywords.** Urine antigen detection; *Streptococcus pneumoniae*; polysaccharide.
in urine, serum, and sputum samples [12, 13]. In 1999, a rapid non–culture-based screening method for evaluating S. pneumoniae infection was introduced and marketed as the BinaxNOW S. pneumoniae assay. This assay detects pneumococcal C-polysaccharide in urine samples from patients with pneumonia but is not serotype specific. However, both techniques have either low specificity or sensitivity, or require large sample volumes or expensive technology.

To improve diagnosis of pneumococcus, a 13-valent Luminex multiplex urinary antigen detection (UAD) assay that identifies serotypes covered by the 13-valent PCV (PCV13; Prevnar 13®, Pfizer) was developed and validated [14, 15]. This assay combines multiple spectrally distinct microspheres conjugated to a different serotype-specific monoclonal antibodies (mAbs) in a single test to simultaneously detect 13 pneumococcal polysaccharide (PnPS) serotypes in a small volume of urine. The UAD assay demonstrated 97% sensitivity and 100% specificity when validated against samples from bacteremic patients with CAP of known cause [14] and provided a robust tool for clinical and epidemiological evaluation of pneumococcal disease (PD) in adults [16, 17].

UAD assays offer an alternative to other serotyping methods for both invasive and noninvasive disease. The original UAD assay (UAD-1) identified the PCV13 serotypes. Because new PCVs are under development with increased serotype coverage, we developed the UAD-2 assay, which is capable of detecting additional pneumococcal serotypes. The current article describes the development, qualification, and clinical validation of a UAD-2 assay that identifies 11 additional non-PCV13 pneumococcal serotypes (serotypes 2, 8, 9N, 10A, 11A, 12F, 15B, 17F, 20, 22F, and 33F). Combined with the original UAD-1 assay, 24 S. pneumoniae serotypes can be identified with high sensitivity and specificity in patients with invasive PD (IPD) or noninvasive PD.

**MATERIALS AND METHODS**

**Reagents and Assay Specificity**

Serotype specific reagents were generated as described elsewhere [14]. After screening for suitable mAbs and polyclonal antibodies, the specificity of the UAD-2 assay was assessed with urine samples from healthy donors spiked with PnPS (Supplementary Material).

**Positivity Cutoffs**

Like the original UAD-1 assay, the UAD-2 is a limit assay [15]. To determine UAD-2 positivity cutoffs, 48 reference standard curves were generated for each serotype to ensure the suitability of the 11-point reference standard. Positivity cutoffs (antigen concentrations read from a standard curve) were established for each serotype, using 400 control urine specimens obtained from individuals undergoing elective surgery, healthy patients with stable chronic obstructive pulmonary disease (COPD), and healthy donors with no apparent signs of PD. Nonparametric tolerance intervals were computed from these concentrations, giving a range predicted to contain 98% of negative urine samples with 99% confidence, thus achieving ≥97% assay specificity for each serotype [18]. The positivity cutoffs were refined using additional samples (400 control urine samples from healthy adults and 110 urine samples from patients with chest radiographically confirmed CAP and a corresponding BC obtained from a sterile site (BC or pleural fluid)).

**Multiplex Serotype-specific UAD-2 Assay**

The UAD-2 assay was performed as described elsewhere [14], with some modifications such as use of automated Tecan Fluent-1080 Luminex Systems and FlexMap-3D readers (Luminex). All samples were tested in duplicate and scored as serotype positive if both duplicate values were greater than the serotype-specific positivity cutoff. Statistical analyses and data processing were performed using a validated SAS program version 9.4.

**Assay Qualification**

Assay robustness was assessed using a fractional factorial design of experiment to study various assay robustness factors (day, operator, primary incubation time and temperature, secondary incubation time and temperature, reporter antibody time and temperature). Qualification consisted of assay runs over multiple days that addressed precision, sample linearity, and accuracy, as described elsewhere, with some modification [15] (Supplementary Material).

**Study Participants and Clinical Validation**

To clinically validate the diagnostic potential of the UAD-2 assay, we evaluated urine specimens obtained from patients >18 years old with radiographically confirmed CAP, who were enrolled in a multicenter US epidemiological study [19]. This study included 11 087 patients with CAP with corresponding urine samples and BCs obtained from a sterile site (BC or pleural fluid). Of the 11 087 patients, 10 220 had nonbacteremic and 867 had bacteremic CAP diagnosed. The etiological agent in a bacteremic CAP case was supported by positive BC.

For clinical validation of the sensitivity and specificity of the UAD-2 assay, the BC in patients with CAP was considered the “true” result. The 867 positive BC results represented 144 S. pneumoniae and 723 non–S. pneumoniae organisms. Of the 144 S. pneumoniae BCs, 17 were not serotyped and were excluded from the determination of sensitivity and specificity. Of the 723 non–S. pneumoniae organisms, 260 were potential contaminating organisms (Bacillus sp, coagulase-negative Staphylococcus sp, Corynebacterium sp, and Propionibacterium sp) but were included in the sensitivity and specificity analyses so as not to bias results by excluding potential true cases of bacteremic CAP.
Urinary samples were analyzed in the BinaxNOW S. pneumoniae urine antigen test (Abbott) according to the manufacturer’s instructions. All work was approved by local research ethics committees. Written informed consent was obtained from all enrolled patients.

RESULTS

Assay Specificity
The specificity of the 11-valent UAD-2 assay was assessed using bacterial lysates obtained from 93 S. pneumoniae strains and 413 non-S. pneumoniae organisms (Table 1) spiked into assay buffer. Reactivity to bacterial lysates was assessed using a signal-to-noise ratio (S/N) >5 (PnPS-specific mAb coated bead median fluorescence intensity compared with assay buffer median fluorescence intensity). Of the 93 S. pneumoniae bacterial lysates tested in the UAD-2 assay, 19 had S/N ratios >5 (serotypes 2, 8, 9N, 10A, 11A, 11D, 11F, 12F, 15B, 15C, 17A, 17F, 20A, 20B, 22A, 22F, 33A, 33F, and 39; data not shown). Subsequently, purified PnPS of these 19 serotypes were then used to make mock samples by spiking them individually into assay buffer at 10 ng per well (approximately 40–200 times the saturating concentration), which were then tested using the UAD-2 assay. In all cases, homologous PnPS mAb-coated microspheres produced S/N ratios greater than tested using the UAD-2 assay. In all cases, homologous PnPS mAb-coated microspheres produced S/N ratios greater than 5 to PnPS.

Assay Qualification
To classify a test sample as positive using the UAD-2 assay requires a fluorescent signal above the positivity cutoff, because the UAD-2 is a limit assay. Relevant to the validation of a limit assay are sensitivity, precision, and specificity according to published nomenclature for bioanalytical validation [20, 21]. Table 1. Specificity of the Urinary Antigen Detection 2 Assay With Crude Bacterial Antigens of 413 Non–Streptococcus pneumoniae Organisms

| Strain                        | Gram Staining | Number Analyzed |
|-------------------------------|---------------|-----------------|
| Acinetobacter speciesb        | Negative      | 7               |
| Aerococcus viridans           | Positive      | 2               |
| Alcaligenes faecalis          | Negative      | 1               |
| Bacillus speciesb             | Positive      | 4               |
| Candida albicans              | Yeast         | 15              |
| Candida speciesb              | Yeast         | 2               |
| Citrobacter koseri            | Negative      | 1               |
| Corinamonas acidovorans       | Negative      | 1               |
| Corynebacterium aculeans      | Positive      | 2               |
| Enterobacter cloace            | Negative      | 14              |
| Enterobacter speciesb         | Negative      | 3               |
| Enterococcus speciesb         | Negative      | 2               |
| Escherichia coli              | Negative      | 15              |
| Haemophilus haemolyticus      | Negative      | 1               |
| Haemophilus influenzae        | Negative      | 63              |
| Haemophilus parahaemolyticus  | Negative      | 3               |
| Haemophilus parainfluenza     | Negative      | 39              |
| Klebsiella oxytoxica          | Negative      | 7               |
| Klebsiella ozaeae             | Negative      | 1               |
| Klebsiella pneumonia          | Negative      | 47              |
| Kocuria rosea                 | Positive      | 2               |
| Lactobacillus species         | Positive      | 1               |
| Leuconostoc species           | Positive      | 1               |
| Moraxella catarrhalis         | Negative      | 11              |
| Neisseria speciesb            | Negative      | 8               |
| Pantoea speciesb              | Negative      | 3               |
| Proteus speciesb              | Negative      | 3               |
| Pseudomonas aeruginosa        | Negative      | 14              |
| Raistonia picketti            | Negative      | 1               |
| Salmonella group D            | Negative      | 1               |
| Serratia liquefaciens         | Negative      | 1               |
| Serratia marcescens           | Negative      | 5               |
| Shawnella algae               | Negative      | 1               |
| Staphylococcus aureus         | Positive      | 45              |
| Staphylococcus epidermidis    | Positive      | 14              |
| Staphylococcus hominis        | Positive      | 6               |
| Staphylococcus species        | Positive      | 8               |
| Staphylococcus warreni        | Positive      | 5               |
| Stenotrophomonas maltophilia  | Negative      | 2               |
| Streptococcus mitis           | Positive      | 11              |
| Streptococcus oralis          | Positive      | 10              |
| Streptococcus parasanguinis   | Positive      | 5               |
| Streptococcus species (other)  | Positive      | 24              |
| Versinia spp.                 | Negative      | 1               |

Table 1. Specificity of the Urinary Antigen Detection 2 Assay With Crude Bacterial Antigens of 413 Non–Streptococcus pneumoniae Organisms

*No cross-reaction was observed among the 413 non–Streptococcus pneumoniae organisms except for 2 of the 11 isolates of S. mitis in the urinary antigen detection 2 assay.

†Including ≥2 unique species. A total of 83 unique organisms were tested in the urinary antigen detection 2 assay.

the precision and sample linearity analyses were used to determine accuracy by comparing each point on the reference curve’s back-calculated concentration value to the expected value. Each serotype’s standard curve bias range was within 80%–125% (Table 3).
Table 2. Specificity of *Streptococcus pneumoniae* Urinary Antigen Detection 2 Assay

| *Streptococcus pneumoniae* Serotype | 2 | 8 | 9N | 10A | 11A | 12F | 15B | 17F | 20 | 22F | 33F |
|-----------------------------------|---|---|---|-----|-----|-----|-----|-----|----|-----|-----|
|                                   | MFI | S/N | MFI | S/N | MFI | S/N | MFI | S/N | MFI | S/N | MFI | S/N | MFI | S/N | MFI | S/N | MFI | S/N | MFI | S/N | MFI | S/N |
| 2                                 | 31 | 264<sup>b</sup> | 125 | 1   | 156 | 1   | 175 | 1   | 176 | 1   | 165 | 1   | 149 | 1   | 211 | 1   | 58  | 1   | 76  | 1   | 72  | 1   |
| 8                                 | 119 | 1   | 40 364<sup>b</sup> | 215<sup>c</sup> | 214 | 1   | 223 | 1   | 277 | 1   | 297 | 1   | 239 | 1   | 226 | 1   | 100 | 1   | 129 | 1   | 120 | 1   |
| 9N                                | 121 | 1   | 193 | 1   | 46 264<sup>c</sup> | 213<sup>b</sup> | 215 | 1   | 274 | 1   | 293 | 1   | 220 | 1   | 233 | 1   | 99  | 1   | 126 | 1   | 116 | 1   |
| 10A                               | 125 | 1   | 239 | 1   | 241 | 1   | 44 340<sup>b</sup> | 209<sup>b</sup> | 312 | 1   | 304 | 1   | 271 | 1   | 229 | 1   | 99  | 1   | 155 | 1   | 119 | 1   |
| 11A                               | 141 | 1   | 204 | 1   | 239 | 1   | 232 | 1   | 41 537<sup>d</sup> | 165<sup>b</sup> | 294 | 1   | 246 | 1   | 211 | 1   | 102 | 1   | 150 | 1   | 130 | 1   |
| 12F                               | 119 | 1   | 189 | 1   | 235 | 1   | 240 | 1   | 314 | 1   | 36 941<sup>b</sup> | 130<sup>b</sup> | 231 | 1   | 227 | 1   | 99  | 1   | 129 | 1   | 106 | 1   |
| 15B                               | 102 | 1   | 161 | 1   | 205 | 1   | 219 | 1   | 226 | 1   | 242 | 1   | 40 514<sup>c</sup> | 180<sup>b</sup> | 212 | 1   | 78  | 1   | 105 | 1   | 93  | 1   |
| 17F                               | 122 | 1   | 219 | 1   | 235 | 1   | 222 | 1   | 275 | 1   | 300 | 1   | 372 | 2   | 45 191<sup>b</sup> | 210<sup>b</sup> | 98  | 1   | 137 | 1   | 137 | 1   |
| 20<sup>c</sup>                    | 133 | 1   | 212 | 1   | 268 | 1   | 218 | 1   | 249 | 1   | 280 | 1   | 219 | 1   | 207 | 1   | 36 435<sup>b</sup> | 368<sup>b</sup> | 131 | 1   | 113 | 1   |
| 22F                               | 121 | 1   | 188 | 1   | 227 | 1   | 205 | 1   | 264 | 1   | 284 | 1   | 251 | 1   | 194 | 1   | 98  | 1   | 30 236<sup>c</sup> | 243<sup>c</sup> | 127 | 1   |
| 33F                               | 136 | 1   | 185 | 1   | 230 | 1   | 215 | 1   | 302 | 1   | 306 | 1   | 229 | 1   | 212 | 1   | 103 | 1   | 428 | 3   | 45 312<sup>c</sup> | 405<sup>b</sup> |
| 39                                | 102 | 1   | 141 | 1   | 162 | 1   | 39 893<sup>b</sup> | 140<sup>b</sup> | 206 | 1   | 250 | 1   | 375 | 1   | 264 | 1   | 287 | 1   | 226 | 1   |
| 11D                               | 125 | 1   | 200 | 1   | 645 | 3   | 205 | 1   | 41 112<sup>b</sup> | 163<sup>b</sup> | 283 | 1   | 218 | 1   | 207 | 1   | 103 | 1   | 126 | 1   |
| 11F                               | 128 | 1   | 197 | 1   | 228 | 1   | 225 | 1   | 27 157<sup>d</sup> | 108<sup>b</sup> | 268 | 1   | 226 | 1   | 294 | 1   | 105 | 1   | 379 | 3   | 152 | 1   |
| 15C                               | 128 | 1   | 666 | 4   | 271 | 1   | 481 | 2   | 562 | 2   | 280 | 1   | 224 | 1   | 94  |<sup>b</sup> | 206 | 1   | 94  | 1   | 129 | 1   |
| 17A                               | 139 | 1   | 214 | 1   | 2  | 1   | 235 | 1   | 278 | 1   | 322 | 1   | 246 | 1   | 2377<sup>b</sup> | 112<sup>b</sup> | 107 | 1   | 135 | 1   | 198 | 2   |
| 20A                               | 113 | 1   | 169 | 1   | 226 | 1   | 212 | 1   | 222 | 1   | 235 | 1   | 204 | 1   | 189 | 1   | 5963<sup>b</sup> | 60<sup>b</sup> | 162 | 1   | 96  | 1   |
| 22A                               | 131 | 1   | 201 | 1   | 221 | 1   | 222 | 1   | 258 | 1   | 303 | 1   | 231 | 1   | 236 | 1   | 105 | 1   | 27 277<sup>b</sup> | 219<sup>b</sup> | 120 | 1   |
| 33A                               | 128 | 1   | 195 | 1   | 234 | 1   | 215 | 1   | 252 | 1   | 281 | 1   | 239 | 1   | 232 | 1   | 104 | 1   | 140 | 1   | 30 833<sup>b</sup> | 273<sup>b</sup> |

Abbreviations: mAb, monoclonal antibody; MFI, median fluorescence intensity; S/N, signal-to-noise ratio.

<sup>a</sup>*S. pneumoniae* serotypes consisted of 10 ng/well purified pneumococcal polysaccharide spiked in urine that was tested negative for any *S. pneumoniae* pneumococcal polysaccharide.

<sup>b</sup>Serotype reactivity with S/N ratio >5.

<sup>c</sup>Structural analysis indicates serotype 20B.
Table 3. *Streptococcus pneumoniae* Urinary Antigen Detection 2 Assay Serotype Ranges Based on Precision, Sample Linearity, and Accuracy

| Serotype | Positivity Cutoff Value, PnPS U/mL | Assay Range, PnPS U/mL |
|----------|-----------------------------------|------------------------|
| 2        | 60.6                              | 6.3–1541.7             |
| 8        | 38.3                              | 1.3–108.3              |
| 9N       | 49.4                              | 0.7–159.7              |
| 10A      | 48.1                              | 2.2–58.0               |
| 11A      | 48.0                              | 2.2–58.0               |
| 12F      | 61.4                              | 2.6–631.9              |
| 15B      | 79.1                              | 3.6–32.2               |
| 17F      | 103.2                             | 2.6–625.0              |
| 20       | 13.9                              | 1.9–369.6              |
| 22F      | 29.0                              | 0.7–314.5              |
| 33F      | 275                               | 1.3–322.9              |

Abbreviation: PnPS U/mL, pneumococcal polysaccharide units/mL.

Table 4. Assay Ranges for Final *Streptococcus pneumoniae* Urinary Antigen Detection 2 Assay

| Serotype | Positivity Cutoff Value, PnPS U/mL | Final Assay Ranges, PnPS U/mL |
|----------|-----------------------------------|-----------------------------|
| 2        | 60.6                              | 6.3–1541.7                  |
| 8        | 38.3                              | 1.3–108.3                   |
| 9N       | 49.4                              | 0.7–159.7                   |
| 10A      | 48.1                              | 2.2–58.0                    |
| 11A      | 48.0                              | 2.2–58.0                    |
| 12F      | 61.4                              | 2.6–631.9                   |
| 15B      | 79.1                              | 3.6–32.2                    |
| 17F      | 103.2                             | 2.6–625.0                   |
| 20       | 13.9                              | 1.9–369.6                   |
| 22F      | 29.0                              | 0.7–314.5                   |
| 33F      | 275                               | 1.3–322.9                   |

Abbreviation: PnPS, pneumococcal polysaccharide.

The final assay range of the UAD-2 assay for each serotype was based on the most conservative values obtained for accuracy, precision, and sample linearity. The serotype-specific final lower and upper limits ranged from 0.7 to 8.1 and from 32.2 to 1541.7 PnPS U/mL, respectively. For all serotypes, the positivity cutoffs fell within the linear range of the UAD-2 assay (Table 4).

Clinical Validation of the UAD-2 Assay

To determine the diagnostic accuracy of the UAD-2 assay, we analyzed 11,087 urine specimens obtained from patients with radiographically confirmed CAP. The cause of CAP was determined for 867 bacteremic patients with a corresponding BC-positive result. Of 867 patients with CAP, 144 had BC-confirmed *S. pneumoniae*. Of 144 BCs, 64 were positive for UAD-2 *S. pneumoniae* serotypes and used to determine sensitivity. Of the 64 corresponding urine samples, 59 were positive with the UAD-2 assay for the exact *S. pneumoniae* serotype shown by BC (Table 5), and 5 were negative with the UAD-2 assay (92.2% sensitivity). To determine specificity, all BC-positive sample results negative for a UAD-2 serotype were compared with UAD-2 test results. Of the 867 BC samples from patients with CAP, 803 had results that were either nonserotyped (n = 17), non-UAD-2 *S. pneumoniae* serotypes (n = 63), or non-*S. pneumoniae* organisms (n = 723). The nonserotyped results were removed from specificity calculations because discrimination between UAD-2 and non–UAD-2 serotypes could not be determined; therefore, specificity was based on the remaining 786 samples.

Overall, the UAD-2 assay identified 32 positive samples from this population (n = 786), which resulted in a specificity of 95.9% against a reference standard of bacteremic pneumonia (Table 5). Within the 32 UAD-2–positive results, 5 urine samples from the 63 patients with a corresponding BC positive for an *S. pneumoniae* serotype not covered by the UAD-2 assay were also positive with the UAD-2 assay (Table 5). In addition, 27 of the 723 samples from patients with bacteremic CAP with BCs positive for etiological agents other than *S. pneumoniae* were positive with the UAD-2 assay (Table 5). Of 723 non–*S. pneumoniae* organisms, 260 were potential contaminants. Removal of these samples from the analysis did not appreciably affect specificity (96.6%). By comparison, the BinaxNOW test was positive for 32 of 64 samples that were BC positive for serotypes covered with the UAD-2 assay and was positive for 33 of 63 samples that had corresponding BC-positive results for *S. pneumoniae* serotypes not covered by the UAD-2 assay, resulting in sensitivities of 50% and 52.4%, respectively (Table 5). Of 867 CAP cases with bacteremic pneumonia, 11.5% were UAD-2 serotypes (22F [3.58%], 20 [1.27%], 33F [1.38%], 11A [1.38%], 9N [1.04%], 12F [0.92%], 8 [0.81%], 17F [0.58%], 15B [0.46%], and 10A [0.35%]) (Table 6). There were no BC-positive results for serotype 2.

### UAD-2 Serotype Distribution in Nonbacteremic CAP

After determining sensitivity and specificity in bacteremic CAP, the UAD-2 assay was used to assess serotype distribution in nonbacteremic CAP. The assay identified all 11 serotypes in an additional 3.72% of urine samples obtained from patients with nonbacteremic CAP (380 of 10,220; Table 6). The BinaxNOW test demonstrated *S. pneumoniae* in 547 of 10,220 samples (5.4%) from patients with nonbacteremic CAP. Of these 547 samples, 100 were also positive with the UAD-2 assay. Within the nonbacteremic CAP population, the percentages of individual UAD-2 serotypes positive with the UAD-2 assay were as follows: 22F, 0.89%; 11A, 0.74%; 9N, 0.45%; 10A, 0.43%; 33F, 0.25%; 8, 0.25%; 17F, 0.23%; 12F,
Bacteremic CAP, including CAP, vary according to the published literature and reflect study design variability and the sensitivity and specificity of laboratory methods to detect and type pneumococci. In addition, the introduction of PCVs into routine immunization programs has substantially altered pneumococcal epidemiology, including serotype distribution, over time. Lack of a reference standard test to determine the pneumococcal etiological agent makes performance assessments of any diagnostic test challenging [22]. For example, lung puncture has been used but requires an accessible consolidation and is an invasive procedure. Bronchoalveolar lavage has been used but is limited to patients ill enough to require intubation and may not access bacteria in the lung periphery.

The standard method for confirming and serotyping IPD cases is the capsular swelling/Quellung reaction [10, 23]; however, this technique requires isolation of viable bacteria from blood, has low sensitivity, does not identify nonbacteremic CAP [24], and relies on the subjective interpretation of assay results. The BinaxNOW test, reported as 86% sensitive for IPD, detects pneumococcal C-polysaccharide in urine by means of an immunochromatographic membrane assay; however, lower sensitivities (52%–82%) have been reported in studies involving adults with CAP [14, 25–27]. More importantly, the BinaxNOW is not a serotype-specific test. Therefore, UAD assays that identify pneumococcal serotypes in urine samples from patients with CAP have clear advantages [14, 15].

Although it is desirable to have high assay sensitivity to accurately assess serotype-specific disease burden, the focus of the assay was to achieve high specificity to ensure that the regulatory end point of vaccine efficacy (and potential effectiveness) could be obtained with high validity. Therefore, positivity cutoffs achieving ≥97% assay specificity for each serotype were established from donors without evidence of PD. In particular, samples from patients with COPD were included in this assessment, because these individuals demonstrate higher carriage rates and approximately 35%–47% of patients with CAP are assumed to

Table 5. Clinical Validation of the Urinary Antigen Detection 2 Assay

| BC Results                        | Cases, Number | Negative, Number | Positive, Number | Sensitivity vs BC, % | Specificity vs BC, % |
|-----------------------------------|---------------|------------------|------------------|----------------------|----------------------|
| **BC positive** (bacteremic CAP)  |               |                  |                  |                      |                      |
| Total                             | 867           | 772              | 95               | ...                  | 106                  |
| UAD-2 serotypes                   | 64            | 5                | 59               | 92.2                 | NA                   |
| Non–UAD-2 serotypes              | 63            | 58               | 5                | NA                   | 92.1                 |
| Non–Streptococcus pneumoniae     | 723           | 696              | 27               | NA                   | 96.3                 |
| Total non–UAD-2 S. pneumoniae and non–S. pneumoniae | 786 | 754 | 32 | NA | 95.9 |
| **BC negative** (nonbacteremic CAP) | 10 220      | 9840             | 380            | NA                   | 547                  |
| Total CAP (bacteremic and nonbacteremic) | 11 087    | 10 612           | 475             | NA                   | 653                  |

Abbreviations: BC, blood culture; CAP, community-acquired pneumonia; NA, not applicable; UAD-2, urinary antigen detection 2.

**Table 6. Distribution of Urinary Antigen Detection 2 Serotypes (Bacteremic and Nonbacteremic Community-acquired Pneumonia)**

| Serotypes | Bacteremic CAP (n = 10 220) | Nonbacteremic CAP (n = 11 087) |
|-----------|-----------------------------|--------------------------------|
| 2         | 3 (0.03)                    | 3 (0.03)                       |
| 8         | 26 (0.25)                   | 33 (0.30)                      |
| 9N        | 46 (0.45)                   | 55 (0.50)                      |
| 10A       | 44 (0.43)                   | 47 (0.42)                      |
| 11A       | 76 (0.74)                   | 88 (0.79)                      |
| 12F       | 22 (0.22)                   | 30 (0.27)                      |
| 15B       | 16 (0.16)                   | 20 (0.18)                      |
| 17F       | 24 (0.23)                   | 29 (0.26)                      |
| 20        | 18 (0.18)                   | 29 (0.26)                      |
| 22F       | 91 (0.89)                   | 122 (1.10)                     |
| 33F       | 26 (0.25)                   | 38 (0.34)                      |
| Total     | 380 (3.72)                  | 480 (4.33)                     |

Abbreviations: CAP, community-acquired pneumonia; UAD-2, urinary antigen detection 2.

The No. (%) in Table 6 refers to Patients No. (%).

Downloaded from https://academic.oup.com/cid/advance-article-abstract/doi/10.1093/cid/ciaa158/5740223 by guest on 10 May 2020
have COPD [28]. Further studies are needed to evaluate the sensitivity of the UAD-2 assay when used in other populations (ie, patients from other geographic locations, patients in different age groups [eg, infants and toddlers], those with immunodeficiencies, and those living in high-transmission settings, such as crowded households), especially in regions where carriage rates are higher than in the United States.

Like the UAD-1 assay, the UAD-2 assay demonstrated excellent robustness, analytical specificity, accuracy, precision, and sample linearity around the positivity cutoffs (Tables 2–4 and Supplementary Tables 1 and 2), and its sensitivity was better than that of other urine based S. pneumoniae tests [25–27, 29–31]. The high specificity and sensitivity of the UAD-2 assay are primarily due to the use of serotype-specific mAbs. Cross-reactivity between some serotypes was observed, particularly for closely related serotypes; in particular, mAb cross-reactivity between serotypes 10A and 39 is based on structural similarities and was observed elsewhere [31]. Despite these cross-reactivities, the UAD-2 assay’s usefulness is not diminished substantially, because the proportion of CAP cases due to these cross-reacting serotypes is low in IPD, except for serogroup 15, where both serotypes 15B and 15C are identified.

Clinical validation is often assessed by comparison to a predicate method or reference standard. For the UAD-2 assay, a measured result was compared with what was considered a “true result” from BC/typed samples. During clinical validation, the UAD-2 assay was 92.2% sensitive and 95.9% specific to BC results (Table 5). However, the sensitivity for nonbacteremic pneumonia is unknown because of the lack of a reference standard. Our clinical validation study suggests that there is a large burden of pneumonia due to the 11 serotypes in the UAD-2 assay that cannot be detected by BC. This is likely to be an underestimate, because the cutoffs were assigned to drive specificity, which may result in some nonbacteremic pneumonia cases, for UAD-2 serotypes being classified as negative.

Evidence for this possibility comes from a public health analysis of a large randomized, controlled trial of PCV13 among Dutch adults aged ≥65 years [32, 33]. The study’s prespecified primary outcome was vaccine type, radiographically confirmed CAP, with vaccine type determined primarily based on UAD-1 assay positivity. For the primary outcome, the rate reduction for vaccine-preventable disease was 25.1 cases per 100 000 person-years of observation. By comparison, for clinical CAP, based only on criteria with no requirement for etiological or radiographic confirmation, the rate reduction was 72.2 per 100 000 person-years (2.8-fold greater).

This increase in rate reduction likely resulted largely from a lack of chest radiographic sensitivity; however, lower UAD assay sensitivity (to achieve high specificity) could also be a contributing factor. Consequently, radiographically confirmed CAP with UAD-1 and/or UAD-2 assay results should be considered minimum estimates of the contribution of these serotypes to pneumonia. In addition, sensitivity and specificity may be underestimated because the UAD-2 assay can type >1 S. pneumoniae serotype in a sample, whereas serotyping using the Quellung reaction relies on sampling morphologically distinct S. pneumoniae colonies on a BC plate and is prone to analyst bias. Likewise, accurate typing methods, like UAD assays, are needed because more than one serotype can cause IPD [34–36]. Overall, clinical validation results demonstrated high sensitivity and specificity and indicate that the UAD-2 serotype-specific positivity cutoffs are appropriate. By comparison, the BinaxNOW test was less sensitive (50.0%; Table 5) than the UAD-2 assay in identifying S. pneumoniae in individuals with an S. pneumoniae BC result.

Other urine-based PnPS serotype-specific multiplex immunoassays have been described [31, 37]. The method described by Eletu et al [31] is significantly different from the UAD-2 assay. First, positivity is based on a test-to-negative control value being ≥2. In contrast, the positivity cutoffs of the UAD-2 assay are diagnostic cutoffs calibrated to a serotype-specific reference standard. Second, the analytical specificity for each serotype was broad and could limit the accuracy of serotype-specific epidemiological assessments of PD burden or vaccine effectiveness. Third, the assay described is not designed to adjust the positivity cutoffs to account for potential differences in colonization state or urine compositions in geographically diverse non-CAP populations that may require such adjustments. For example, non pneumococcal organisms that express S. pneumoniae capsule have been isolated from individuals without CAP [38, 39]. Carriage of such non pneumococcal organisms in healthy individuals may elevate urine polysaccharide levels. Therefore, for this reason and others previously discussed, geographically relevant “healthy control” urine samples are needed for each study to confirm that the serotype positivity cutoffs accurately separate carriage from disease.

In addition, several studies have demonstrated that S. pneumoniae antigens can be detected in the urine up to 3 months after infection [29, 40] and 7 days after vaccination with PnPS vaccine [41]. Thus, UAD assay results should take into account clinical and chest radiographic findings at the time urine specimens are obtained, and samples for UAD assays should not be collected shortly after S. pneumoniae vaccination. In addition, PnPS has been reported in the urine of healthy infants (2–60 months) with upper respiratory tract colonization [29]. Urinary PnPS detection in young children may not discriminate between carriage and disease when adult cutoffs are used. Therefore, these tests are not recommended for use in pediatric populations unless cutoffs are adjusted to allow differentiation between carriage and disease in these pediatric populations.
In conclusion, this article describes the development/qualifica-
tion and clinical validation of a highly sensitive and specific 
UAD-2 assay for diagnosing 11 clinically relevant S. pneumoniae 
serotypes. Because BC is likely to remain the reference standard 
for diagnosing IPD, the main value of the UAD-2 assay will be 
for assessing serotype-specific nonbacteremic CAP, which ac-
counts for the majority of PD cases [9]. In addition, Luminex 
technology allows flexibility to add additional serotypes to a 
UAD assay, which may be important to assess future serotype-
specific PD epidemiology not covered by UAD-1 and UAD-2 
assays. In combination with the UAD-1 assay, the UAD-2 assay 
may be useful in monitoring PD epidemiology after the intro-
duction of future pneumococcal vaccines, determining the ef-
cacy and effectiveness of future vaccines, and providing the 
data needed for decision makers to arrive at evidence-based 
decisions regarding pneumococcal vaccine choice and target 
populations.

Supplementary Data
Supplementary materials are available at Clinical Infectious Diseases online. Consisting of data provided by the authors to benefit the reader, the posted materials are not copyrighted and are the sole responsibility of the authors, so questions or comments should be addressed to the corresponding author.

Notes
Author contributions. All authors contributed to research and develop-
ment of the urinary antigen detection 2 assay, associated studies, and 
drafting of the manuscript, and all authors have read and approved the final 
manuscript.
Acknowledgments. Scott Vuocolo, PhD, from Pfizer, provided editorial assistance. The authors also thank William Gruber, MD for extensive review of this manuscript.
Financial support. This work was supported by Pfizer.
Potential conflicts of interest. All authors are current or former Pfizer 
employees. All authors have submitted the ICMJE Form for Disclosure of 
Potential Conflicts of Interest. Conflicts that the editors consider relevant to the 
content of the manuscript have been disclosed.

References
1. Angouquant F, Levy C, Grimpel E, et al. Early impact of 13-valent pneumococcal 
conjugate vaccine on community-acquired pneumonia in children. Clin Infect 
Dis 2014; 58:918–24.
2. Jain S, Self WH, Wunderink RG, et al; CDC EPIC Study Team. Community-
acquired pneumonia requiring hospitalization among U.S. adults. N Engl J Med 
2015; 373:415–27.
3. Jokinen C, Heiskanen L, Juvonen H, et al. Incidence of community-acquired 
pneumonia in the population of four municipalities in eastern Finland. Am J 
Epidemiol 1993; 137:977–88.
4. Woodhead MA, Macfarlane JT, McCracken JS, Rose DH, Finch RG. Prospective 
study of the aetiology and outcome of pneumonia in the community. Lancet 
1987; 1:671–4.
5. Ramirez JA, et al. Adults hospitalized with pneumonia in the United States: inci-
dence, epidemiology, and mortality. Clin Infect Dis 2017; 65:1806–12.
6. GBD 2013 Mortality and Causes of Death Collaborators. Global, regional, 
and national age-sex specific all-cause and cause-specific mortality for 240 causes of 
death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 
2013. Lancet 2015; 385:117–71.
7. Madhi SA, Klugman KP. Vaccine Trialist Group. A role for Streptococcus pneumoniae 
in virus-associated pneumonia. Nat Med 2004; 10:811–3.
8. Huang SS, Johnson KM, Ray GT, et al. Healthcare utilization and cost of pneumo-
coccal disease in the United States. Vaccine 2011; 29:3398–412.
9. Pakhale S, Mulpuru S, Verheij TJM, Kochen MM, Rohde GGU, Bjerre LM. Antibiotics for community-acquired pneumonia in adult outpatients. Cochrane 
Database of Systematic Reviews 2014:1–55. doi:10.1002/14651858.CD002109. 
pub4.
10. Austrian R. The Quellung reaction, a neglected microbiologic technique. Mt Sinai 
J Med 1976; 43:699–709.
11. Rosón B, Carratalá J, Verdaguer R, Dorea J, Manresa F, Gudiol F. Prospective study 
of the usefulness of sputum Gram stain in the initial approach to community-
acquired pneumonia requiring hospitalization. Clin Infect Dis 2000; 31:869–74.
12. Lenthe-Eboa S, Brighouse G, Auckenthaler R, et al. Comparison of immunolog-
ical methods for diagnosis of pneumococcal pneumonia in biological fluids. Eur J 
Clin Microbiol 1987; 6:28–34.
13. Farrington M, Rubenstein D. Antibiotic detection in pneumococcal pneumonia. J 
Infect 1991; 23:109–16.
14. Pride MW, Huijts SM, Wu K, et al. Validation of an immunodiagnostics assay for 
detection of 13 Streptococcus pneumoniae serotype-specific polysaccharides in 
human urine. Clin Vaccine Immunol 2012; 19:1131–41.
15. Pride MW, Gaulitz RU. Reevaluation of positivity cutoff values for the pneumo-
coccal urinary antigen detection assay. Clin Vaccine Immunol 2017; 24:e00239–17.
16. Sherwin RL, Gray S, Alexander R, et al. Distribution of 13-valent pneumo-
coccal conjugate vaccine Streptococcus pneumoniae serotypes in US adults aged 
≥50 years with community-acquired pneumonia. J Infect Dis 2013; 208:1813–20.
17. Centers for Disease Control and Prevention. Active bacterial core surveillance 
report, Emerging Infections Program network. Streptococcus pneumoniae, 2010. 
Atlanta, GA: Centers for Disease Control and Prevention, 2011. Available at: http://www.cdc.gov/abcs/reports-findings/surveireports/sprevol10.pdf.
18. Hahn GJ, Meeker WQ. Statistical intervals: a guide for practitioners. John Wiley 
& Sons, New York, NY; John Wiley 1991.
19. Isturiz RE, Ramirez J, Self WH, et al. Pneumococcal epidemiology among us adults 
hospitalized for community-acquired pneumonia. Vaccine 2019; 37:3352–61.
20. International Conference on Harmonisation. Validation of analytical proced-
ures: text and methodology Q2 (R1). Presented at: International Conference on 
Harmonisation; 2005; Geneva, Switzerland.
21. Rovers MM, Glasziou P, Appelman CL, et al. Antibiotics for acute otitis media: a 
meta-analysis with individual patient data. Lancet 2006; 368:1429–35.
22. Klugman KP, Madhi SA, Albracht WC. Novel approaches to the identification of 
Streptococcus pneumoniae as the cause of community-acquired pneumonia. Clin Infect 
Dis 2008; 47(suppl 3):S202–6.
23. O'Brien KL, Nohynek H; World Health Organization Pneumococcal Vaccine 
Trials Carriage Working Group. Report from a WHO working group: standard 
method for detecting upper respiratory carriage of Streptococcus pneumoniae. 
Pediatr Infect Dis J 2003; 22:e1–11.
24. Arai S, Konda T, Wad A, et al. Use of antisera-coated latex particles for sero-
typing Streptococcus pneumoniae. Microbiol Immunol 2001; 45:159–62.
25. Ishida T, Hashimoto T, Arita M, Tojo Y, Tachibana H, Innami M. A 3-year pro-
spective study of a urinary antigen-test detection for Streptococcus pneumoniae 
in community-acquired pneumonia: utility and clinical impact on the reported 
etiology. J Infect Chemother 2004; 10:359–63.
26. Murdoch DR, Laing RT, Mills GD, et al. Evaluation of a rapid 
immunochromatographic test for detection of Streptococcus pneumoniae 
anigen in urine samples from adults with community-acquired pneumonia. J Clin 
Microbiol 2001; 39:3495–8.
27. Strälin K, Kaltoft MS, Konradsen R, Holmberg H. Comparison of two 
urinary antigen tests for establishment of pneumococcal etiology of adult 
community-acquired pneumonia. J Clin Microbiol 2004; 42:3620–5.
28. Fry AM, et al. Trends in hospitalizations for pneumonia among persons aged 
65 years or older in the United States, 1988–2002. JAMA 2005; 294:2712–9.
29. Leeming JP, Cartwright K, Morris R, Martin SA, Smith MD; South-West 
Pneumococcus Study Group. Diagnosis of invasive pneumococcal infection by 
serotype-specific urinary antigen detection. J Clin Microbiol 2005; 43:4972–6.
30. Rosario M, Capeding Z, Nohynek H, Ruutu P, Leinonen M. Evaluation of a new 
tube latex agglutination test for detection of type-specific pneumococcal antigens 
in urine. J Clin Microbiol 1991; 29:1818–21.
31. Eletu SD, Sheppard CL, Thomas E, et al. Development of an extended-specificity 
multiplex immunoassay for detection of Streptococcus pneumoniae serotype-
specific antigen in urine by use of human monoclonal antibodies. Clin Vaccine 
Immunol 2017; 24:1–17.
32. Gesner BD, Jiang Q, Van Werkhoven CH, et al. A public health evaluation of 
13-valent pneumococcal conjugate vaccine impact on adult disease outcomes 
from a randomized clinical trial in the Netherlands. Vaccine 2019; 37:7577–87.
33. Hak E, Grobbee DE, Sanders EA, et al. Rationale and design of CAPITA: a RCT 
of 13-valent conjugated pneumococcal vaccine efficacy among older adults. Neth 
J Med 2008; 66:378–83.
34. Harboe ZB, Thomsen RW, Riis A, et al. Pneumococcal serotypes and mortality following invasive pneumococcal disease: a population-based cohort study. PLoS Med 2009; 6:e1000081.
35. Johnson HL, et al. Systematic evaluation of serotypes causing invasive pneumococcal disease among children under five: the pneumococcal global serotype project. PLoS Med 2010; 7:1–13.
36. Isaacman DJ, McIntosh ED, Reinert RR. Burden of invasive pneumococcal disease and serotype distribution among Streptococcus pneumoniae isolates in young children in Europe: impact of the 7-valent pneumococcal conjugate vaccine and considerations for future conjugate vaccines. Int J Infect Dis 2010; 14:e197–209.
37. Sheppard CL, Guiver M, Hartley J, Harrison TG, George RC. Use of a multiplexed immunoassay for detection of serotype-specific Streptococcus pneumoniae antigen in pleural fluid and cerebrospinal fluid specimens. J Med Microbiol 2011; 60:1879–81.
38. Lessa FC, Milacky J, Rouphael NG, et al. Streptococcus mitis expressing pneumococcal serotype 1 capsule. Sci Rep 2018; 8:17959.
39. Pimenta F, Gertz RE Jr, Park SH, et al. Streptococcus infantis, Streptococcus mitis, and Streptococcus oralis strains with highly similar cps5 loci and antigenic relatedness to serotype 5 pneumococci. Front Microbiol 2018; 9:3199.
40. Andreo F, Prat C, Ruiz-Manzano J, et al. Persistence of Streptococcus pneumoniae urinary antigen excretion after pneumococcal pneumonia. Eur J Clin Microbiol Infect Dis 2009; 28:197–201.
41. Priner M, Cornillon C, Forestier D, Valero S, Paccalin M. Might Streptococcus pneumoniae urinary antigen test be positive because of pneumococcal vaccine? J Am Geriatr Soc 2008; 56:170–1.